210 related articles for article (PubMed ID: 24379032)
21. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
22. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
Berhanu P; Perez A; Yu S
Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
[TBL] [Abstract][Full Text] [Related]
23. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
DePaoli AM; Higgins LS; Henry RR; Mantzoros C; Dunn FL;
Diabetes Care; 2014 Jul; 37(7):1918-23. PubMed ID: 24722496
[TBL] [Abstract][Full Text] [Related]
24. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
25. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
26. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
27. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
28. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
30. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
[TBL] [Abstract][Full Text] [Related]
31. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
[TBL] [Abstract][Full Text] [Related]
34. The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.
Tooke JE; Elston LM; Gooding KM; Ball CI; Mawson DM; Piper J; Sriraman R; Urquhart R; Shore AC
Diabetologia; 2006 May; 49(5):1064-70. PubMed ID: 16508777
[TBL] [Abstract][Full Text] [Related]
35. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
36. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
[TBL] [Abstract][Full Text] [Related]
37. Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.
Biesenbach G; Grafinger P; Raml A
Wien Klin Wochenschr; 2006 Sep; 118(17-18):543-8. PubMed ID: 17009067
[TBL] [Abstract][Full Text] [Related]
38. The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Strowig SM; Raskin P
Diabetes Care; 2005 Jul; 28(7):1562-7. PubMed ID: 15983301
[TBL] [Abstract][Full Text] [Related]
39. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
Aljabri K; Kozak SE; Thompson DM
Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
